THE hypoglycaemic effect of the sulphonylurea family of drugs was long suspected to be secondary to endogenous insulin release from the pancreatic islets. This was confirmed by Yalow et al. (1960) who showed a rise in peripheral plasma concentration of insulin after tolbutamide administration to normal subjects. More recently, Coore & Randle (1964) showed that, when isolated segments of rabbit pancreas were incubated in the presence of tolbutamide, there was additional release of insulin into the medium.
Further evidence that the sulphonylurea drugs increase pancreatic islet-cell activity emerged from the thorough studies of Fajans et al. (1963) and Floyd et al. (1963) . These authors showed that, whereas the amino acid, L-leucine, induced only a modest rise in peripheral plasma insulin concentration in normal subjects, the response was dramatically enhanced by pre-treatment of these subjects with chlorpropamide. Floyd et al. (1966) have since shown that infusion of a number of amino acids, including L-arginine, is followed by a rise in peripheral plasma insulin levels. We have confirmed that arginine infusion initiates a rise in plasma insulin concentration. There is, in addition, a rise in plasma HGH concentration after arginine, a response which is quantitatively greater in the female than in the male (Merimee, Lillicrap & Rabinowitz, 1965; Merimee, Burgess & Rabinowitz, 1966 (Fig. 2) ; (b) when the mean change in peripheral insulin levels was compared (Table 3) ; and (c) when the individual plasma insulin responses to arginine were examined (Fig. 3) .
From the last analysis, there was a suggestion Without pre-treatment Mean +20-6 +25-2 +8-1 +0-7 +0-4 +0-4 SEM 9-4 6-6 2-6 3.2 3-0 2-4
Following chlorpropamide pre-treatment Mean +16-2 +22-5 +3-9 +1-3 -4-4 -4-9 SEM 8-0 9-8 5-6 6-7 4-2 3-6 * Arginine monochloride infused from time zero to time 30. Data were analysed by comparing each individual's plasma insulin levels after arginine with his basal insulin concentration. All values are ,U/ml. that chlorpropamide may reduce the plasma response to arginine: five of seven subjects showed a lesser response to arginine after chlorpropamide (Fig. 3) . HGH (Table 4 , Fig. 4) We have previously reported that male subjects show a variable HGH response to arginine infusion (Merimee et al., 1965) . This observation was confirmed in the present study: six subjects failed to obtain a rise in plasma HGH (5 ng/ml or above) after arginine, the other subject (L.A.) did (Table 4) The data were also examined to determine whether the increase in basal plasma insulin levels after chlorpropamide was obscuring any change in responsiveness. The mean increment in plasma insulin after arginine was 25-2 juU/ml before and 22-5 juU/ml after sulphonylurea pre-treatment. Five of the seven subjects exhibited a decrease in the arginine-initiated rise in plasma insulin following chlorpropamide pre-treatment (Fig. 3) . We conclude, therefore, that sulphonylurea pre-treatment does not enhance arginine-initiated insulin release in normal males, in whom we believed there was the greatest chance of detecting any augmentation. Our findings appear to be similar to the experiments already reported in abstract form by Floyd et al. (1965) .
It is possible that leucine and arginine provoke insulin release by different mechanisms. It may be useful, therefore, to explore whether insulin release initiated by these two amino acids differs in ways other than the disparate response to sulphonylurea pre-treatment. For example, we have shown that (Rabinowitz et al., 1966a, b) . Also, Fajans et al. (1966) have evidence that diazoxide may reduce insulin release after leucine.
It will be of interest to determine the influence of epinephrine on leucine-initiated insulin release and of diazoxide on arginine-initiated hormonal release.
We next turn our attention to arginine-initiated HGH release in male subjects. We have previously reported (Merimee et al., 1966) 
